Fiorentini Giammaria, Sarti Donatella, Ranieri Girolamo, Gadaleta Cosmo Damiano, Fiorentini Caterina, Milandri Carlo, Mambrini Andrea, Guadagni Stefano
Department of Onco-Hematology, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", Pesaro 61122, Italy.
Oncology Department, Ospedale S. Maria Della Misericordia, ASUR1, Urbino 61029, Italy.
World J Clin Oncol. 2021 Nov 24;12(11):1064-1071. doi: 10.5306/wjco.v12.i11.1064.
An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electro-hyperthermia (mEHT) results in increased survival and tumor response.
To compare outcomes of CHT alone or in association with mEHT for the treatment of stage III and IV pancreatic cancer.
This was an observational retrospective study; data were collected for patients with stage III-IV pancreatic cancer that were treated with CHT alone or in combination with mEHT from 2003 to 2019. A total of 158 patients were included in the study out 270 patients screened in four Italian hospitals; 58 (37%) of these received CHT + mEHT and 100 (63%) CHT. CHT was mainly gemcitabine-based regimens in both groups.
Overall (19.5 mo 11.02 mo, < 0.001) and progression-free (12 mo 3 mo, < 0.001) survival were better for the CHT + mEHT group compared to the CHT group. The association of mEHT resulted also in an improvement of tumor response with disease control rate 95% 58% ( < 0.001) at 3 mo. Toxicity was comparable in the two study groups, and mEHT related adverse events were limited in 8 patients presenting G1-2 skin burns.
The addition of mEHT to systemic CHT improved overall and progression-free survival and local tumor control with comparable toxicity.
越来越多的研究报道了区域热疗联合化疗（CHT）和放疗治疗胰腺癌的有益效果；特别是，调制式电超热疗法（mEHT）的使用可提高生存率并改善肿瘤反应。
比较单纯CHT或联合mEHT治疗III期和IV期胰腺癌的疗效。
这是一项观察性回顾性研究；收集了2003年至2019年接受单纯CHT或联合mEHT治疗的III-IV期胰腺癌患者的数据。在四家意大利医院筛查的270例患者中，共有158例纳入研究；其中58例（37%）接受CHT+mEHT，100例（63%）接受CHT。两组的CHT主要都是以吉西他滨为基础的方案。
与CHT组相比，CHT+mEHT组的总生存期（19.5个月 11.02个月，P<0.001）和无进展生存期（12个月 3个月，P<0.001）更好。mEHT的联合使用还改善了肿瘤反应，3个月时疾病控制率为95% 58%（P<0.001）。两个研究组的毒性相当，8例出现1-2级皮肤烧伤的患者发生的与mEHT相关的不良事件有限。
在全身CHT基础上加用mEHT可改善总生存期和无进展生存期，并实现局部肿瘤控制，且毒性相当。
